FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2024”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of June 2024 we identify the following current VC trends in Europe:
Total Healthcare & Life Sciences funding reached EUR 4,110m.
Biotech received 59% of the total investment volume (EUR 2,439m) with oncology being the leading indication (50%).
In June, Bright Peak Therapeutics (Switzerland) secures the highest transaction volume with EUR 83m, followed by iOnctura (Switzerland) with EUR 80m and UroMems (France) with EUR 44m.
European Innovation Council Fund (Belgium) is the most active investor (by deal volume), followed by M&G Investments (United Kingdom) and Patient Square Capital (United States).
To access the full report, please click here.